| Assessment Status | Rapid Review Complete |
| HTA ID | 25060 |
| Drug | Semaglutide |
| Brand | Ozempic® |
| Indication | Semaglutide (Ozempic®) 2mg is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications • in addition to other medicinal products for the treatment of diabetes. |
| Assessment Process | |
| Rapid review commissioned | 06/10/2025 |
| Rapid review completed | 23/10/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that semaglutide (Ozempic®) 2mg solution for injection not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here